Literature DB >> 8018594

Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production.

S Watanabe1, H Yssel, Y Harada, K Arai.   

Abstract

The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018594     DOI: 10.1093/intimm/6.4.523

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

Review 1.  Cyclic AMP: a selective modulator of NF-κB action.

Authors:  Sarah Gerlo; Ron Kooijman; Ilse M Beck; Krzysztof Kolmus; Anneleen Spooren; Guy Haegeman
Journal:  Cell Mol Life Sci       Date:  2011-07-09       Impact factor: 9.261

2.  Cyclic AMP suppresses interleukin-5 synthesis by human helper T cells via the downregulation of the calcium mobilization pathway.

Authors:  O Kaminuma; A Mori; K Ogawa; H Kikkawa; A Nakata; K Ikezawa; H Okudaira
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production.

Authors:  L S Harbige; L Layward; M M Morris-Downes; D C Dumonde; S Amor
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 4.  Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3.

Authors:  Laurence S Harbige
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

5.  Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells.

Authors:  E R Fedyk; R P Phipps
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

6.  Characterization of cis-regulatory elements of the c-myc promoter responding to human GM-CSF or mouse interleukin 3 in mouse proB cell line BA/F3 cells expressing the human GM-CSF receptor.

Authors:  S Watanabe; S Ishida; K Koike; K Arai
Journal:  Mol Biol Cell       Date:  1995-06       Impact factor: 4.138

Review 7.  Prostaglandin E2 and T cells: friends or foes?

Authors:  Vinatha Sreeramkumar; Manuel Fresno; Natalia Cuesta
Journal:  Immunol Cell Biol       Date:  2011-09-27       Impact factor: 5.126

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.